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To evaluate the clinical response of five children 
with automatic atrial tachycardia (AA T) and as- 
sociated cardiomyopathy to arrhythmia control, 
we compared pretreatment and posttreatment 24- 
hour ECG heart rates, cardiothoracic ratio by 
chest radiograph, and echocardiographic mea- 
sures of ventricular ,function. Two children were 
treated with amiodarone, two with surgical exci- 
sion and cryoablation of the ectopic focus, and one 
with digoxin alone. Signijicantly slower mean 
heart rates were achieved, along with a dominant 
sinus rhythm and improvement in symptoms. 
Control of the AAT resulted in improved mean 
cardiothoracic ratio (0.53 pre vs 0.49 post; P 
= 0.021, as well as improvement in a number of 
echocardiographic measurements: mean shorten- 
ingfraction (20% pre vs 34% post; P = 0.006), 
mean ejection fraction (36% pre vs 50% post; P 
< 0.01), mean velocity of’ circumferential fiber 
shortening (0.62 pre vs 1.20 post; P = 0.003). 
Mean E-point septa1 separation corrected for end- 
diastolic dimension also showed a trend toward 
improvement (0.25 pre vs 0.16 post; P = 0.11). 
Right ventricular endocardial biopsies in four were 
nonspecific; an atrial biopsy from surgery showed 
a Purkinje fiber-like tissue in one patient, but was 
nonspecijic in another. We conclude that cardio- 
myopathy can be causally linked to automatic 
atrial tachycardia and that aggressive medical 
and/or surgical management is warranted in those 
patients with signs and symptoms of impaired ven- 
tricular function. (J Interven Cardiol 1989:2:4) 
Introduction 
Supraventricular tachycardia (SVT) from an ec- 
topic automatic atrial focus, herein called auto- 
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matic atrial tachycardia (AAT), accounts for 
< 10% of SVT in children’,’ is usually slower than 
the more common reentrant forms of SVT, and 
may be virtually incessant. At one time considered 
AAT, in the absence of structural heart 
disease, has recently been associated with cardio- 
myopathy (CM). Although AAT is often refractory 
to conventional medical therapy, several reports 
suggest that control of the arrhythmia improves 
cardiac perf~rmance.~~’ In recent years, new phar- 
macologic agents8-’ ’ as well as surgical exci- 
and catheter electrical ablation20-22 have 
led to successful control of intractable AAT. To 
further examine the proposition that control of 
persistent AAT favorably alters cardiac function in 
some patients with cardiomyopathy, we compared 
the clinical course and noninvasive measures of 
sion 12-1 9 
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ventricular function before and after therapy in 
five children with AAT. In addition, the findings 
of two right atrial and three right ventricular biop- 
sies obtained from these patients are summarized. 
Recommendations for treatment based on this ex- 
perience are outlined. 
Methods 
Five patients referred to the Pediatric Arrhyth- 
mia Clinic at C.S. Mott Children’s Hospital, Uni- 
versity of Michigan, exhibited poorly controlled, 
virtually incessant SVT (Fig. 1) and had developed 
fatigue, exercise intolerance, increased heart size 
on chest radiograph, and echocardiographic find- 
ings of decreased ventricular function, suggestive 
of cardiomyopdthy. Four patients underwent elec- 
trophysiologic study (EPS) using programmed ex- 
trastimulation (PES), overdrive pacing, and map- 
ping of atrial activation during the tachycardia. 
Four patients had hemodynamic study and two 
right ventricular endom yocardial biopsy; one had 
a right ventricular biopsy and two atrial biopsies at 
surgery. The diagnosis of automatic atrial tachy- 
cardia (AAT) was based upon the criteria of Gol- 
[initiation of the 
tachycardia by spontaneous atrial depolarizations 
identical to successive atrial depolarizations dur- 
ing the tachycardia, independence of the tachycar- 
dia cycle length on AV node conduction, succes- 
et al. and 
sive shortening of the tachycardia cycle length 
after the initial several beats (“warm up”), atrial 
depolarization during the tachycardia that reset 
the atrial cycle, and failure of a single or a train of 
atrial premature depolarizations to initiate or in- 
terrupt the tachycardia]. In one patient the diag- 
nosis was made by the surface ECG and Holter 
tracings alone (initiating P wave of the tachycardia 
as the same morphology of the subsequent beats, 
“warm-up” period, and atrioventricular dissocia- 
tion during SVT). Persistent junctional reciprocat- 
ing tachycardia was excluded by either the absence 
of 1 : 1 atrioventricular conduction during the 
tachycardia or the absence of ventriculoatrial con- 
duction during ventricular pacing as well. The se- 
lection of medical or surgical treatment was based 
upon the duration of the patient’s symptoms, their 
anticipated compliance with a medical regimen, 
and, in two patients, their decision against chronic 
antiarrhythmic medication. 
Response to therapy was evaluated by pre- and 
posttreatment 24-hour ambulatory electrocardio- 
graphic tracings (CardioData Corp., Northboro, 
MA, USA), chest radiographs, and two-dimen- 
sional and M-mode echocardiograms (Advanced 
Technology Laborotones, Seattle, WA, USA and/ 
or Acuson Computer Sonography, Mountain 
View, CA, USA). All five patients were free of val- 
vular, congenital, ischemic or other structural 
heart disease by two-dimensional echocardiogram, 
Doppler analysis, and cineangiography (four pa- 
. . . . . . . . . . .  . , . a  ! ; : 1 .,. ’ I: ;I :.I . .  
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Figure 1. Representative EUG tracings from leads I1 and 111 from patient #4 before and after final treatment. Note the pretreatment 
heart rate of 125 bpm and the inverted P waves in both leads (left hand tracings). Following trealment the rate is 75 bpm and the P waves 
are upright in both leads (right hand tracings). 
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tients). Cardiac rhythm and mean 24-hour heart 
rates were determined by computer generated 
analysis and confirmed by full disclosure tracings. 
The cardiothoracic ratio (CTR) was measured 
from the chest radiograph in the posterior-anterior 
projection during maximal inspiration. The left 
ventricular shortening fraction (SF), mean veloc- 
ity of circumferential fiber shortening corrected 
for heart rate (VCF,), E-point septal separation 
normalized for end-diastolic demension (EPSS/ 
EDD) were measured from the M-mode echocar- 
diogram; the left ventricular ejection fraction (EF) 
determined from the apical four-chamber view of 
the two-dimensional echocardiogram was calcu- 
lated using the Simpson's rule algorithm. All pre- 
treatment studies were obtained within 1 week 
prior to initiation of therapy. The mean interval 
between pre- and posttreatment examination was 
1.5 years. Results are expressed as the mean * one 
standard deviation and are compared using a 
paired t-test. Differences in the mean were consid- 
ered significant when the P value was 10.05. 
Results 
Symptoms. The clinical data are summarized in 
Table I. All patients complained of easy fatigabil- 
ity, two noted dizziness, and one had exercise in- 
tolerance. Electrophysiological study in four pa- 
tients localized the origin of the AAT at the coro- 
nary sinus 0s in two patients and the low septal 
right atrium in one. In the fourth patient, earliest 
atrial activation during SVT occurred both at the 
mouth of the coronary sinus and the atrioventricu- 
lar node, suggesting that the abnormal impulse 
arose equidistant between these two points. He- 
modynamic studies in the four patients undergo- 
ing electrophysiologic study demonstrated a mean 
left ventricular end-diastolic pressure (LVEDP) 
of 16 mmHg (range 10-26 mmHg), and a mean 
cardiac index of 2.8/min/m2 (range 1.6-3.2 
L/min/m2). 
Treatment. An average of 2.3 drug trials were 
used in three patients before satisfactory control of 
the AAT was achieved (Table I). Digoxin alone 
provided adequate control in only one patient. 
Beta blockade was ineffective in the two patients in 
whom it was tried. Two patients, ages 9 and 11 
years, received amiodarone therapy for control of 
the SVT. After initial success with amiodarone, 
atrioventricular block occurred in one of these pa- 
tients. Amiodarone was withdrawn and flecainide 
initiated with a return of control of the tachycar- 
dia. The remaining two patients, ages 15 and 20 
years, who had received digoxin and propranolol 
Table I. Clinical, Therapeutic, Biopsy, and Follow-up Data 
SVT 
Heart Duration of Duration of 
Current Duration Rate Early Conventional Subsequent Myocardial Subsequent 
Patient Age of SVT (bgm) Symptoms Treatment Therapy Treatment Biopsy Outcome Treatment 




2 9.8 years 0.6 years 135 fatigue digoxin 
3 11.3 years 0.1 year 175 fatigue, dyspnea digoxin 
4 14.1 years 13.8 years 130 fatigue, digoxin 
dizziness 




2 years amiodarone 
0.5 year amiodarone 
- digoxin 
flecainidc 
13 years cryodblation/ 


















NSR 1.5 years 
90% NSR 1.0 year 
I O'% SVT 0.5 year 
NSR 1 .O year 
60% NSR 3 years 
40% SVT 
NSR 3 years 
RARE APB 
APB = atrial premature beat; bpm = beats per minute; NSR = normal sinus rhythm; R = right: RAA = right atrial appendage; SVT = supraventricular 
tachycardia; Vent = ventricle. 
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16-  
1 4 -  
1 2 -  
1 0 -  
0 8  
0 6  
0 4  
02 
either alone or together for greater than 13 years, 
elected surgery. The five patients have been fol- 
lowed for an average of 1.5 years. 
Heart Rate and Cardiothoracic Ratio. There was 
a significant (P I 0.002) reduction in the mean 
heart rate (128 f 24 vs 91 f 10 bpm) as deter- 
mined by 24-hour ambulatory electrocardiograms. 
The dominant mechanism of the post-treatment 
cardiac rhythm was sinus (Fig. 1) in all five pa- 
tients. Patients 1-3 were treated medically, and 
each required adjustments of the medication, in- 
cluding other antiarrhythmia trials, for satisfactory 
control (a few isolated atrial premature beats). Pa- 
tient 4 had marked reduction in the incidence and 
persistence of SVT but still had runs of tachycar- 
dia. Patient 5 is virtually free of arrhythmia with 
only a few isolated atrial premature beats and a 
normal heart rate response to treadmill exercise 
(i.e., no ectopic tachycardia during exercise). 
Along with the above noted return to a slower 
:g 
SHORTENING FRACTION 
EF 0 .6 -  
0.5 - 
0 4 -  
0 3 -  
0 2 -  
SF 
0 s  
0 2  





sinus rhythm, there was a significant reduction in 
the CTR by chest x-ray (53% precontrol vs 49% 
postcontrol, P = 0.02). 
Echocardiographic Measures of Ventricular 
Function. Figure 2 summarizes the improvement 
in cardiac function. Both the systolic and diastolic 
dimensions significantly decreased yielding an im- 
proved shortening fraction (mean 2 I % to mean 
34%, P I 0.05). The two-dimensional echocardio- 
graphic ejection fraction, reflecting a more global 
measurement, also increased from a mean 36% to 
mean 50% following control of the tachycardia (P 
I 0.01). The mean heart rate corrected VCF in- 
creased from a mean of 0.62 to a mean of 1.20 
circs/sec (P = 0.003). The EPSS/EDD, a measure 
independent of preload, was abnormal (i.e., 
greater than 0.2-the 95th percentile) in three of 
the five patients prior to treatment. Although one 
of these three remained >95th percentile following 





BEFORE AFTER BEFORE AFTER 
0.1 
Figure 2. Echocardiographic measures of left ventricular function before and after final treatment in the five 
patients. SF = shortening fraction; VCF, = velocity of circumferential fiber shortening corrected for heart 
rate; EF = ejection fraction: EPSS/EDD = E-point septa1 separalion/end-diastolic dimension. 
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Patient 2 is of particular interest (Fig. 3). Amio- 
darone successfully restored sinus rhythm but was 
discontinued because of hyperactivity possibly re- 
lated to hyperthyroxinemia. Although flecainide 
replaced the amiodarone, the AAT resumed. After 
thyroid function was determined to be normal, 
amiodarone was restarted with return to sinus 
rhythm. Thus, during two separate treatment pe- 
nods over a 6-month period, a direct relationship 
between the control of the tachycardia and normal 
echocardiographic measured cardiac function was 
observed. 
Myocardial Biopsies. Light microscopic exami- 
nation of the biopsies from the right ventricle 
showed no evidence for myocarditis or storage 
disease in any patient. Nonspecific myofibril hy- 
pertrophy and focal fibrosis that were within the 
range of normal were present in two patients 
(Table I). The atrial biopsy from patient 4 dis- 
closed normal atrial tissue. In contrast, the atrial 
EPSS/EDD VCVF 













NORXI RXI N O W  RX2 







0.0 1 0 . 1  
NORX1 RXI NORX2 RX2 
Figure 3. Echocardiographic measures of left ventricular function in patient # I  during two 
trials of amiodarone. The interval between NORX 1 and RX 1 is 7 months; between RX 1 
and NORXZ, 14 months: and between NORXZ and RX2,4 months. EPSS/EDD = E-point 
septa1 separation/end-diastolic dimension; VCF, = velocity of circumferencial fiber shorten- 
ing corrected for heart rate: SF = shortening fraction; EF = ejection fraction. 
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tissue excised from patient 5 during surgery dem- 
onstrated Purkinje fiber-like tissue in specimens 
from the coronary sinus, the mapped origin of his 
tachycardia, as well as from the right atrial ap- 
pendage (Table I). 
Complications. No significant complications 
were encountered. Patient 2 required evaluation of 
his thyroid function because of the suspicion d a t  
he might be thyrotoxic. However, further thyroid 
studies excluded this possibility and amiodarone 
was resumed. Patient 4 experienced 2: 1 heart 
block postoperatively, but permanent normal 1 : 1 
conduction resumed within 5 days. 
Follow-up. All patients except patient 4 are 
asymptomatic and virtually free of their tachyar- 
rhythmia at mean 1.5 years following treatment. 
Following control of the tachycardia, three pa- 
tients resumed full activity, and the other two have 
had a marked but not complete return to previous 
activity level. Patient 4 was recently hospitalized 
following a suicide attempt. Non-invasive evalua- 
tion at that time disclosed normal left ventricular 
function by echocardiogram, normal cardiac size 
on chest radiograph, normal exercise treadmill 
test, normal sinus rhythm during 12 of the 24 
hours on Holter electrocardiography, and much 
less tachycardia that during the pretreatment pe- 
riod. Because of a complex social situation, further 
cardiac and arrhythmia evaluation was deferred. 
Discussion 
Our data are in accord with the observations of 
others that indicate that sustained automatic atrial 
tachycardia at only moderately elevated rates 
above normal ( 120- 1 70 bpm) may produce signif- 
icant impairment of cardiac function. Further- 
more, our experience demonstrates that this im- 
pairment is associated with the appearance of 
symptoms. Finally, our experience confirms not 
only improved control of the tachycardia follow- 
ing pharmacological and/or surgical intervention, 
but also, as a result, significant recovery of cardiac 
The exact causal relationship between chronic 
atrial tachycardia and the development of a car- 
diomyopathic state has not been fully established. 
Recent s t u d i e ~ ~ ~ - ~ ~  have demonstrated that ven- 
tricular pacing of the canine heart at accelerated 
function.6.7. 13,1426 
rates produces congestive heart failure in 2-3 
weeks. Although no direct evidence for a similar 
effect of chronic atrial pacing has been reported, 
the association of sustained supraventricular 
tachycardia and congestive heart failure in in- 
f a n t ~ ~ ~ , ~ '  as well as in older individuals4 has been 
recognized for several decades. The progression to 
a myopathy is less clear. Nonetheless, a number of 
repo~s6.7,13,16-18,26 that indicate resolution ofa di- 
lated heart after control of supraventricular tachy- 
cardia, along with our experience, support these 
experimental data. Patient 3 represents a fortui- 
tous clinical experiment supporting those observa- 
tions. This patient demonstrated over a 6-month 
period a direct relationship between control of the 
tachycardia and improvement in ventricular func- 
tion. Further, the observation from our two oper- 
ated patients that the return of cardiac function 
was not instantaneous suggests that the observed 
change in the echocardiographic measures of ven- 
tricular function are not simply a function of heart 
rate but reflect genuine improvement in ventricu- 
lar performance. 
Previous  report^'^,^^,^^ have suggested Purkinje- 
like or mesenchymal type tumors causing auto- 
matic tachycardia as well as other complex ar- 
rhythmias; on the other hand atrial biopsies in 10 
other patien& with sustained AAT63'2715.'7*19 were
nonspecific. Patient 5 had Purkinje-like fibers ex- 
cised from the area of tachycardia focus. Interest- 
ingly, similar cells were found in his incidentally 
discarded right atrial appendage taken for cannu- 
lation. These abnormal mesenchymal cells/Pur- 
kinje fibers argue against a cardiac muscle abnor- 
mality as the cause of the AAT and lead to the 
possibility of multiple subclinical abnormal cells 
in patients with automatic atrial tachycardia, giv- 
ing rise to the possibility of late recurrence. In 
contrast, the atrial tissue excised from Patient 4 
failed to disclose unusual cells, perhaps suggesting 
an incomplete ablation of her ectopic focus and, 
thus, explaining, in part, her less successful result. 
The nonspecific right ventricular biopsy material 
from our three patients, along with the five re- 
ported by others,6 underscores the absence of a 
primary ventricular abnormality as the proximate 
cause of the observed impairment in cardiac func- 
tion. 
Conventional therapy is rarely effective. Di- 
goxin alone failed to control the SVT in four of our 
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five patients; the addition of beta blockade in two 
patients was also unsuccessful. Both patients who 
received amiodarone converted to sinus rhythm. 
Thus, similar to other  report^,^^,^^ our experience 
suggests that no single therapeutic regimen 
emerges as the clear treatment of choice. Because 
of the infrequency of this disorder, its variable nat- 
ural history, including documented spontaneous 
remission of the t a c h y ~ a r d i a ~ ~ , ~ ~  and the nonran- 
dom use of the different forms of therapy, a single 
optimal treatment for all patients will probably not 
be forthcoming. Thus, a step-wise approach may 
be prudent. In the absence of symptoms and with 
no evidence of impaired ventricular function, ther- 
apy may not be necessary. Because control of the 
tachycardia will restore ventricular function, with 
increasing improvement over time, noninvasive 
evidence for decreased ventricular function war- 
rants treatment. New antiarrhythmic medications, 
including flecainide, encainide, ethmozine, and 
amiodarone,*-" along with the development of 
electrophysiological-cryosurgical 
offer several avenues for management. However 
the recent experience with flecainide and encain- 
ide36 underscores the need for a careful weighing of 
the risks of treatment (as well as no treatment) 
along with the benefits expected before initiating 
unexplored pharmacological therapy. 
Conclusions 
We conclude that AAT may be causally linked 
to the development of cardiomyopathy. Poorly 
controlled AAT may present clinically as conges- 
tive heart failure, or more subtly, with impairment 
of ventricular function prior to the onset of overt 
failure. In the experience reported herein, as well 
as those of others, aggressive management results 
in resolution of the SVT, symptomatic improve- 
ment, and normalization of ventricular function. 
Because AAT is a treatable arrhythmia, any child 
presenting with symptoms, signs, and echocardio- 
graphic evidence of cardiomyopathy should be 
carefully evaluated by ECG, 24-hour ambulatory 
ECG, and, if necessary, electrophysiologic studies. 
Treatment should be instituted if either symptoms 
or the noninvasive findings of decreased ventricu- 























Gillette K. The mechanism of supraventricular tachycar- 
dia in children. Circulation 1976; 54: 133- 139. 
Campbell RM, Dick M, Rosenthal A. Cardiac arrhyth- 
mias in children. Am Rev Med 1984; 35:397-410. 
Keane JF, Plauth WH, Nadas AS. Chronic ectopic tachy- 
cardia of infancy and childhood. Am Heart J 1972; 
Weiss HB, McGuire J. Ectopic tachycardia, auricular in 
origin, of unusual duration. Am Heart J 1936; 12585- 
591. 
Hay JD, Keidan SE. Persistent ectopic auricular tachycar- 
dia in children. Br Heart J 1952; 14:345-349. 
Parker DL, Gust HB, Seth JW, et al. Tachycardia-in- 
duced cardiomyopathy: A reversible form of left ventricu- 
lar dysfunction. Am J Cardiol 1986; 57563-570. 
Kugler JE, Baisch SO, Cheatham JP, et al. Improvement 
of left ventricular dysfunction after control of persistent 
tachycardia. J Pediatr 1984; 105:543-548. 
Evans EL, Garson A Jr, Smith RT, et al. Ethmozine: A 
promising drug for automatic atrial ectopic tachycardia. 
Am J Cardiol 1987; 60:83F-86F. 
Kunze KP, Kuck KH, Schluter M, et al. Effect of Encain- 
ide and Recainide on chronic atrial tachycardia. J Am 
Coll Cardiol 1986; 7: 1 12 1 - 1 126. 
Berns E, Rinkenberger RL, Jeang M, et al. Efficacy and 
safety of flecainide acetate for atrial tachycardia or fibrilla- 
tion. Am J Cardiol 1987; 59:1337-1341. 
Coumel P, Fidelle J. Amiodarone in the treatment of car- 
diac arrhythmias in children: One hundred thirty-five 
cases. Am Heart J 1980; 100: 1063- 1069. 
Wyndham CRC, Arnsdorf MF, Levitsky S, et al. Success- 
ful surgical excision of focal paroxysmal atrial tachycar- 
dia: Observations in vivo and vitro. Circulation 1980; 
Olson SB, Blomstrom P, Sabel KG, et al. Incessant ec- 
topic atrial tachycardia: Successful surgical treatment with 
regression of dilated cardiomyopathy picture. Am J Car- 
diol 1984; 53:1465-1466. 
Josephson ME, Spear JF, Harken AH, et al. Surgical exci- 
sion of automatic atrial tachycardia: Anatomic and elec- 
trophysiologic correlates. Am Heart J 1982; 104: 1076- 
1085. 
Iwa T, Ichihashi T, Hashizume Y, et al. Successful surgical 
treatment of left atrial tachycardia. Am Heart J 1985; 
Ott DA, Garson A, Cooley PA, et al. Definitive operation 
for refractory cardiac tachydysrhythmias in children. J 
Thorac Cardiovasc Surg 1985; 90:68 1-689. 
Frank G, Baumgart D, Klein H, et al. Successful surgical 
treatment of focal atrial tachycardia-a case report and 
review of the literature. J Thorac Cardiovasc Surg 1986; 
Gillette PC, Smith RT. Canon A Jr, et al. Chronic supra- 
ventricular tachycardia, a curable cause of congestive car- 
diomyopathy. J Am Med Assoc 1985; 253:391-392. 
Giorgi LV, Hartzler GO, Hamaker WR. Incessant focal 
atrial tachycardia: A surgically remediable cause of car- 
diomyopathy. J Thorac Cardiovasc Surg 1984; 87:466- 
473. 
Gillette PC, Wamplec PL, Garson A Jr, et al. Treatment of 
atrial automatic tachycardia by ablation procedures. J Am 
Coll Cardiol 1985; 6:405-409. 
Davis J, Scheinman MM, Ruder MA, et al. Ablation of 





Vol. 2, No. 4, 1989 Journal of Interventional Cardiology 217 








treatment of ectopic supraventricular-tachycardia in 
adults. Circulation 1986; 74: 1044-1053. 
Borggrefe M, Breithardt G. Ectopic atrial tachycardia after 
transvenous catheter ablation of a posteroseptal accessory 
pathway. J Am Coll Cardiol 1986; 8:441-445. 
Goldreyer BN, Gallagher JJ, Damato AN. The electro- 
physiologic demonstration of atrial ectopic tachycardia in 
man. Am Heart J 1973; 85:205-215. 
Scheinman MM, &bal B, Hollenberg M. Electrophysio- 
logic studies in patients with persistent atrial tachycardia. 
Circulation 1974; 50:266-273. 
Gillette PC, Garson A Jr. Electrophysiologic and pharma- 
cologic characteristics of automatic ectopic atrial tachy- 
cardia. Circulation 1977; 5657 1-575. 
Gallagher JJ. Tachycardia and cardiomyopathy: The 
chicken-egg dilemma revisited. J Am Coll Cardiol 1985; 
Coleman HN, Taylor RR, Pool PE, etal. Congestive heart 
failure following chronic tachycardia. Am Heart J 197 1 ; 
Wilson JR, Douglas P, Hickey WF, et al. Experimental 
congestive heart failure produced by rapid ventricular 












Armstrong PW, Stopps TP, Ford SE, et al. Rapid ventricu- 
lar pacing in the dog: Pathophysiologic studies of heart 
failure. Circulation 1986; 74: 1075-1084. 
Silverman JJ, Race OM. Paroxysmal tachycardia with a 
ventricular rate of 365 per minute. Am Heart J 1949; 
37: 1 139-1 143. 
Nadas AS, Daeschner CW, Roth A. Paroxysmal tachycar- 
dia in infants and children. Pediatrics 1952; 9 167- 18 1. 
James TN, Beeson CW, Sherman EB, et al. De Subitaneis 
Mortibus, XIII. Multifocal Purkinje cell tumors of the 
heart. Circulation 1975; 52:333-344. 
Rossi L, Piffer R, Turolla E, et al. Multifocal Purkinjslike 
tumor of the heart: Occurrence with other anatomic ab- 
normalities in the atrioventricular junction of an infant 
with junctional tachycardia, LownGanong-Levine syn- 
drome, and sudden death. Chest 1985; 87:340-345. 
Mehta AV, Sanchez GR, Sacks El, et al. Ectopic auto- 
matic atrial tachycardia in children: Clinical characteris- 
tics, management, and follow-up. J Am Coll Cardiol 
Koike K, Hesslein PS, Finlay CD, et al. Atrial automatic 
focus tachycardia in children. Am J Cardiol 1988; 
CAST Investigators. The cardiac arrhythmia suppression 
trial. N Engl J Med 1989; 321:406-412. 
1988; 11~379-385. 
61: 1 127-1 130. 
218 Journal of Interventional Cardiology Vol. 2, No. 4, 1989 
